• Profile

Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus

BMC Gastroenterology Jan 05, 2022

Shimizu H, Fujii T, Kinoshita K, et al. - Intravenous tacrolimus was tested for treatment of acute severe ulcerative colitis and it was found that superior remission and colectomy-free survival rates were conferred by intravenous tacrolimus than oral tacrolimus. Both treatments had a similar safety profile.

  • In a prospective cohort study, 87 hospitalized acute severe ulcerative colitis patients were included; 65 of those received intravenous tacrolimus and 22 received oral tacrolimus.

  • For both treatments, response rates exceeded 50% but were not significantly different.

  • Intravenous tacrolimus was associated with higher remission rate vs oral tacrolimus.

  • At 24 weeks, there were similar relapse-free survival rates with oral and intravenous tacrolimus; however, higher colectomy-free survival rates were observed with intravenous tacrolimus vs oral tacrolimus.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen